Sustained Efficacy and Low Rate of Adverse Events of Dupilumab in Type-2 CRSwNP Over 48 Months. Orlando P, Licci G, Illiano G, Minzoni A, et al. Laryngoscope 2025;135:3104-3111.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Orlando P, Licci G, Illiano G, Minzoni A, et al. Sustained Efficacy and Low Rate of Adverse Events of Dupilumab in Type-2 CRSwNP Over 48 Months. Laryngoscope 2025;135:3104-3111.
PMID: 40265743